Home - X4 Pharmaceuticals

With grit and integrity, we advance novel therapies for individuals with chronic neutropenic disorders. The page tagline says, “Progress for Patients” over an image of the sun rising behind Half Dome in Yosemite National Park. There is a button to

PROGRESS

PATIENTS

Enabling a better future for people with rare immune disorders

recent news

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2024
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
April 30, 2024
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
April 29, 2024

© Copyright 2024 X4 Pharmaceuticals. All Rights Reserved. Terms of Use | Privacy Policy | Consumer Health Data Privacy Policy